GleamWall
中文EN

KRYS Krystal Biotech, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY26.0%
TTM net income YoY13.2%
TTM EPS YoY10.3%
Revenue 3-yr CAGR280.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin48.4%
Net margin47.9%
FCF margin66.0%
EBITDA margin49.7%

Returns

ROE17.5%
ROA15.9%
ROIC (approx.)23.0%
Asset turnover0.33x

Leverage & solvency

Liabilities / assets9.5%
Debt / equity0.00x
Current ratio7.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.44x
Accruals ratio-7.0%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$127.34M$119.22M$116.36M$107.11M$97.80M$96.04M$88.18M$91.14M
R&D expense$14.89M$14.52M$15.33M$14.79M$14.59M$14.41M$14.26M$13.53M
SG&A expense$33.75M$39.85M$41.01M$41.45M$37.58M$35.07M$32.65M$31.29M
Operating income$71.14M$58.42M$53.69M$44.27M$41.37M$39.40M$36.25M$41.38M
Pretax income$80.14M$66.08M$61.44M$51.13M$47.97M$46.77M$43.60M$48.61M
Income tax$17.08M$11.31M$5.51M-$269,000-$31.40M$8.44M$7.86M$3.13M
Net income$63.07M$54.77M$55.93M$51.40M$79.36M$38.33M$35.73M$45.48M
EBITDA$72.64M$59.82M$55.21M$45.83M$42.77M$40.70M$37.66M$42.74M
EPS (basic)2.131.851.91—2.741.331.24—
EPS (diluted)2.051.791.83—2.661.291.20—
Weighted avg. shares (diluted)30.84M30.66M30.51M—29.83M29.75M29.87M—
Balance sheet
Cash & equivalents$462.84M$427.74M$501.31M$496.30M$392.60M$353.83M$308.77M$344.87M
Short-term investments$449.01M$417.89M$322.09M$331.49M$338.46M$328.16M$308.08M$252.65M
Receivables$133.12M$138.66M$127.02M$127.42M$129.63M$111.44M$103.26M$104.75M
Inventory$50.79M$45.56M$42.65M$40.48M$37.63M$31.04M$29.94M$26.51M
Current assets$1.12B$1.06B$1.02B$1.02B$925.65M$841.35M$766.80M$742.04M
PP&E, net$152.29M$153.78M$153.58M$150.78M$148.87M$150.39M$151.07M$155.17M
Total assets$1.59B$1.50B$1.40B$1.33B$1.24B$1.14B$1.07B$1.06B
Current liabilities$142.14M$127.40M$107.80M$102.94M$91.27M$86.90M$79.49M$102.00M
Total liabilities$150.47M$141.52M$120.24M$114.23M$102.22M$97.75M$89.74M$109.46M
Shareholders' equity$1.44B$1.36B$1.28B$1.22B$1.14B$1.04B$984.67M$946.38M
Shares outstanding29.63M29.60M29.44M29.19M28.98M28.93M28.90M28.79M
Cash flow statement
Operating cash flow$91.25M$74.79M$80.38M$77.51M$39.66M$52.73M$30.97M$52.84M
Capital expenditure$996,000$3.56M$7.15M$2.14M$1.70M$1.90M$6.20M$801,000
Free cash flow$90.25M$71.22M$73.23M$75.37M$37.95M$50.83M$24.77M$52.04M
Investing cash flow-$57.98M-$161.58M-$63.58M$11.16M-$4.29M-$10.53M-$54.77M-$83.78M
Financing cash flow$3.41M$15.05M-$10.46M$15.67M$3.71M$1.80M-$12.47M$2.43M
Depreciation & amortization$1.50M$1.40M$1.52M$1.56M$1.40M$1.30M$1.41M$1.36M
Stock-based compensation$13.94M$14.16M$13.61M$13.76M$13.15M$14.12M$13.48M$13.36M

Free plan shows the latest 8 periods; Pro shows all 42 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.